An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer

Jeffrey L Vacirca, Arlene Chan, Klára Mezei, Clarence S Adoo, Zsuzsanna Pápai, Kimberly McGregor, Meena Okera, Zsolt Horváth, László Landherr, Jerzy Hanslik, Steven J Hager, Emad N Ibrahim, Makharadze Rostom, Gajanan Bhat, Mi Rim Choi, Guru Reddy, Karen L Tedesco, Richy Agajanian, István Láng, Lee S Schwartzberg, Jeffrey L Vacirca, Arlene Chan, Klára Mezei, Clarence S Adoo, Zsuzsanna Pápai, Kimberly McGregor, Meena Okera, Zsolt Horváth, László Landherr, Jerzy Hanslik, Steven J Hager, Emad N Ibrahim, Makharadze Rostom, Gajanan Bhat, Mi Rim Choi, Guru Reddy, Karen L Tedesco, Richy Agajanian, István Láng, Lee S Schwartzberg

Abstract

This randomized, open-label, active-controlled study investigated the safety and efficacy of three doses of Rolontis (eflapegrastim), a novel, long-acting myeloid growth factor, versus pegfilgrastim in breast cancer patients being treated with docetaxel and cyclophosphamide (TC). The primary efficacy endpoint was duration of severe neutropenia (DSN) during the first cycle of treatment. Patients who were candidates for adjuvant/neoadjuvant TC chemotherapy were eligible for participation. TC was administered on Day 1, followed by 45, 135, or 270 μg/kg Rolontis or 6 mg pegfilgrastim on Day 2. Complete blood counts were monitored daily when the absolute neutrophil count (ANC) fell to <1.5 × 109 /L. Up to four cycles of TC were investigated. The difference in DSN (time from ANC <0.5 × 109 /L to ANC recovery ≥2.0 × 109 /L) between the Rolontis and pegfilgrastim groups was -0.28 days (confidence interval [CI]: -0.56, -0.06) at 270 μg/kg, 0.14 days (CI: -0.28, 0.64) at 135 μg/kg, and 0.72 days (CI: 0.19, 1.27) at 45 μg/kg. Noninferiority to pegfilgrastim was demonstrated at 135 μg/kg (P = 0.002) and 270 μg/kg (P < .001), with superiority demonstrated at 270 μg/kg (0.03 days; P = 0.023). The most common treatment-related adverse events (AEs) were bone pain, myalgia, arthralgia, back pain, and elevated white blood cell counts, with similar incidences across groups. All doses of Rolontis were well tolerated, and no new or significant treatment-related toxicities were observed. In Cycle 1, Rolontis demonstrated noninferiority at the 135 μg/kg dose and statistical superiority in DSN at the 270 μg/kg dose when compared to pegfilgrastim.

Trial registration: ClinicalTrials.gov NCT01724866.

Keywords: Breast cancer; Rolontis; eflapegrastim; neutropenia.

© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Patient disposition. CONSORT (Consolidated Standards of Reporting Trials) trial flow diagram.
Figure 2
Figure 2
Median absolute neutrophil count by treatment over time (evaluable population). Absolute neutrophil count in patients treated with 45, 135, and 270 μg/kg Rolontis or pegfilgrastim by treatment group in (A) Cycle 1, (B) Cycle 2, (C) Cycle 3, and (D) Cycle 4.

References

    1. Crawford, J. , Dale D. C., and Lyman G. H.. 2004. Chemotherapy‐induced neutropenia: risks, consequences, and new directions for its management. Cancer 100:228–237.
    1. US Department of Health and Human Services . Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published 28 May 2009. Available at: _4.03_2010‐06‐14_QuickReference_5x7.pdf (accessed 8 November 2016).
    1. Aapro, M. S. , Bohlius J., Cameron D. A., Dal Lago L., Donnelly J. P., Kearney N., et al. 2011. 2010 update of EORTC guidelines for the use of granulocyte‐colony stimulating factor to reduce the incidence of chemotherapy‐induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur. J. Cancer 47:8–32.
    1. Ghidini, M. , Hahne J. C., Trevisani F., Panni S., Ratti M., Toppo L., et al. 2016. New developments in the treatment of chemotherapy‐induced neutropenia: focus on balugrastim. Ther. Clin. Risk Manag. 12:1009–1015.
    1. Kuderer, N. M. , Dale D. C., Crawford J., Cosler L. E., and Lyman G. H.. 2006. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266.
    1. Neupogen Package Insert. 2013.
    1. Green, M. D. , Koelbl H., Baselga J., Galid A., Guillem V., Gascon P., et al. 2003. A randomized double‐blind multicenter phase III study of fixed‐dose single‐administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann. Oncol. 14:29–35.
    1. Holmes, F. A. , Jones S. E., O'Shaughnessy J., Vukelja S., George T., Savin M., et al. 2002. Comparable efficacy and safety profiles of once‐per‐cycle pegfilgrastim and daily injection filgrastim in chemotherapy‐induced neutropenia: a multicenter dose‐finding study in women with breast cancer. Ann. Oncol. 13:903–909.
    1. Holmes, F. A. , O'Shaughnessy J. A., Vukelja S., Jones S. E., Shogan J., Savin M., et al. 2002. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high‐risk stage II or stage III/IV breast cancer. J. Clin. Oncol. 20:727–731.
    1. Mey, U. J. , Maier A., Schmidt‐Wolf I. G., Ziske C., Forstbauer H., Banat G. A., et al. 2007. Pegfilgrastim as hematopoietic support for dose‐dense chemoimmunotherapy with R‐CHOP‐14 as first‐line therapy in elderly patients with diffuse large B cell lymphoma. Support. Care Cancer 15:877–884.
    1. Pinto, L. , Liu Z., Doan Q., Bernal M., Dubois R., and Lyman G.. 2007. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta‐analysis of randomized controlled trials. Curr. Med. Res. Opin. 23:2283–2295.
    1. Vogel, C. L. , Wojtukiewicz M. Z., Carroll R. R., Tjulandin S. A., Barajas‐Figueroa L. J., Wiens B. L., et al. 2005. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double‐blind, placebo‐controlled phase III study. J. Clin. Oncol. 23:1178–1184.
    1. Yang, B. B. , Kido A., and Shibata A.. 2007. Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy. Pharmacotherapy 27:1387–1393.
    1. Bondarenko, I. , Gladkov O. A., Elsaesser R., Buchner A., and Bias P.. 2013. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active‐control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. BMC Cancer 13:386.
    1. Gladkov, O. , Moiseyenko V., Bondarenko I. N., Shparyk Y., Barash S., Adar L., et al. 2016. A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. Oncologist 21:7–15.
    1. Kwon, S. C. Determination of binding affinity between G‐CSF receptor and HM10460A. Hanmi Research Center, 10 Sep 2008. Report No.: EF080910. (Not Published).
    1. Kim, Y. H. In vivo Efficacy Study of HM10460A, Long‐Acting G‐CSF, in Neutropenic Mouse Model. Hanmi Research Center, 29 Jun 2007. Report No.: Dvo‐07‐031. (Not Published).
    1. Kim, Y. H. Pharmacodynamic Study of HM10460A in Neutropenic Rats. Hanmi Research Center, 05 Jun 2008. Report No.: Dvo‐08‐004/052. (Not Published).
    1. Neulasta, F. D. A. Medical Review of NDA Application Number 125031/0, 2002.
    1. National Comprehensive Cancer Network . Myeloid Growth Factors (Version 1, 2015). Available at (accessed 22 September 2015).
    1. Blackwell, K. , Donskih R., Jones C. M., Nixon A., Vidal M. J., Nakov R., et al. 2016. A comparison of proposed biosimilar LA‐EP2006 and reference pegfilgrastim for the prevention of neutropenia in patients with early‐stage breast cancer receiving myelosuppressive adjuvant or neoadjuvant chemotherapy: pegfilgrastim randomized oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT‐2), a Phase III, Randomized. Double‐Blind Trial. Oncologist. 21:789–794.
    1. Volovat, C. , Gladkov O. A., Bondarenko I. M., Barash S., Buchner A., Bias P., et al. 2014. Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy. Clin. Breast Cancer 14:101–108.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren